Literature DB >> 17301284

Evaluation of Etest and disk diffusion methods compared with broth microdilution antifungal susceptibility testing of clinical isolates of Candida spp. against posaconazole.

Daniel J Diekema1, Shawn A Messer, Richard J Hollis, Linda B Boyken, Shailesh Tendolkar, Jennifer Kroeger, Michael A Pfaller.   

Abstract

We performed Etest, disk diffusion, and broth microdilution susceptibility testing of 2,171 clinical isolates of Candida spp. against posaconazole. By using provisional breakpoints for comparison purposes only, the categorical agreement between the agar-based methods and broth microdilution results ranged from 93 to 98%, with <1% very major errors. The essential agreement (within 2 well dilutions) between the Etest and broth microdilution methods was 94%. These agar-based methods hold promise as simple and reliable methods for determination of the posaconzole susceptibilities of Candida spp.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17301284      PMCID: PMC1933029          DOI: 10.1128/JCM.02087-06

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  7 in total

1.  Evaluation of Etest method for determining posaconazole MICs for 314 clinical isolates of Candida species.

Authors:  M A Pfaller; S A Messer; K Mills; A Bolmström; R N Jones
Journal:  J Clin Microbiol       Date:  2001-11       Impact factor: 5.948

2.  Evaluation of the Etest and disk diffusion methods for determining susceptibilities of 235 bloodstream isolates of Candida glabrata to fluconazole and voriconazole.

Authors:  M A Pfaller; D J Diekema; L Boyken; S A Messer; S Tendolkar; R J Hollis
Journal:  J Clin Microbiol       Date:  2003-05       Impact factor: 5.948

3.  Correlation between microdilution, E-test, and disk diffusion methods for antifungal susceptibility testing of posaconazole against Candida spp.

Authors:  Charles R Sims; Victor L Paetznick; Jose R Rodriguez; Enuo Chen; Luis Ostrosky-Zeichner
Journal:  J Clin Microbiol       Date:  2006-06       Impact factor: 5.948

4.  Activities of fluconazole and voriconazole against 1,586 recent clinical isolates of Candida species determined by Broth microdilution, disk diffusion, and Etest methods: report from the ARTEMIS Global Antifungal Susceptibility Program, 2001.

Authors:  M A Pfaller; D J Diekema; S A Messer; L Boyken; R J Hollis
Journal:  J Clin Microbiol       Date:  2003-04       Impact factor: 5.948

5.  E-test method for testing susceptibilities of Aspergillus spp. to the new triazoles voriconazole and posaconazole and to established antifungal agents: comparison with NCCLS broth microdilution method.

Authors:  Ana Espinel-Ingroff; A Rezusta
Journal:  J Clin Microbiol       Date:  2002-06       Impact factor: 5.948

6.  Results from the ARTEMIS DISK Global Antifungal Surveillance Study: a 6.5-year analysis of susceptibilities of Candida and other yeast species to fluconazole and voriconazole by standardized disk diffusion testing.

Authors:  M A Pfaller; D J Diekema; M G Rinaldi; R Barnes; B Hu; A V Veselov; N Tiraboschi; E Nagy; D L Gibbs
Journal:  J Clin Microbiol       Date:  2005-12       Impact factor: 5.948

7.  Quality control limits for broth microdilution susceptibility tests of ten antifungal agents.

Authors:  A L Barry; M A Pfaller; S D Brown; A Espinel-Ingroff; M A Ghannoum; C Knapp; R P Rennie; J H Rex; M G Rinaldi
Journal:  J Clin Microbiol       Date:  2000-09       Impact factor: 5.948

  7 in total
  7 in total

Review 1.  Antifungal Susceptibility Testing: Current Approaches.

Authors:  Elizabeth L Berkow; Shawn R Lockhart; Luis Ostrosky-Zeichner
Journal:  Clin Microbiol Rev       Date:  2020-04-29       Impact factor: 26.132

2.  Wild-type MIC distributions and epidemiological cutoff values for posaconazole and voriconazole and Candida spp. as determined by 24-hour CLSI broth microdilution.

Authors:  M A Pfaller; L Boyken; R J Hollis; J Kroeger; S A Messer; S Tendolkar; D J Diekema
Journal:  J Clin Microbiol       Date:  2010-12-15       Impact factor: 5.948

3.  Multicenter comparison of the Vitek 2 antifungal susceptibility test with the CLSI broth microdilution reference method for testing caspofungin, micafungin, and posaconazole against Candida spp.

Authors:  Jess F Peterson; Michael A Pfaller; Daniel J Diekema; Michael G Rinaldi; Katherine M Riebe; Nathan A Ledeboer
Journal:  J Clin Microbiol       Date:  2011-03-23       Impact factor: 5.948

4.  Caspofungin Etest endpoint for Aspergillus isolates shows poor agreement with the reference minimum effective concentration.

Authors:  Jeff Fuller; Adam Schofield; Safeer Jiwa; Crystal Sand; Brad Jansen; Robert Rennie
Journal:  J Clin Microbiol       Date:  2009-12-09       Impact factor: 5.948

5.  Evaluating the resistance to posaconazole by E-test and CLSI broth microdilution methodologies of Candida spp. and pathogenic moulds.

Authors:  R Araujo; S Costa-de-Oliveira; I Coutinho; A G Rodrigues; C Pina-Vaz
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2009-04-07       Impact factor: 3.267

6.  Selection of a surrogate agent (fluconazole or voriconazole) for initial susceptibility testing of posaconazole against Candida spp.: results from a global antifungal surveillance program.

Authors:  M A Pfaller; S A Messer; L Boyken; S Tendolkar; R J Hollis; D J Diekema
Journal:  J Clin Microbiol       Date:  2007-12-19       Impact factor: 5.948

7.  Screening for drug-resistant Candida yeasts with chromogenic agar.

Authors:  William R Kirkpatrick; Joseph D Zimmerman; Fadi P Haikal; Michael J Broker; Erin Brockway; Annette W Fothergill; Dora I McCarthy; Thomas F Patterson; Spencer W Redding
Journal:  Med Mycol       Date:  2010-09       Impact factor: 4.076

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.